Market News

MediciNova (NASDAQ: MNOV) Up Following Grant of Patent

Shares of MediciNova (NASDAQ: MNOV) were on an upswing in pre-market trading on Wednesday as the biopharmaceutical company received a Notice of Allowance from the Canadian Intellectual Property Office for its pending patent application.

This patent application covered MN-001 (tipelukast) and MN-002 (a major metabolite of MN-001) which can be used for reducing cholesterol, trigyceride blood level and reducing low-density lipoprotein (LDL). Once the patent is issued, it is likely to be valid till July 2034.

Kazuko Matsuda, M.D. Ph.D, MPH., Chief Medical Officer, MediciNova commented, “We are very pleased to receive notice that this new patent will be granted. As we already have patents for similar indications in the U.S., Europe, Japan, China, and Korea, we believe this additional patent in Canada could increase the potential value of MN-001.”

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More
Videos